Neuroscience drug discovery and development company Neurim Pharmaceuticals announced on Wednesday that the European Commission has approved an extension of the indication for paediatric prolonged-release melatonin (Slenyto) to include the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).
This followed a recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in January 2025.
Slenyto is a child-appropriate prolonged release melatonin formulation that was first approved in the European Union in 2018 for the treatment of insomnia in children with autism spectrum disorder (ASD) and/or Smith-Magenis Syndrome. In 2024, the indication was extended to neurogenetic disorders (NGDs). Slenyto is the only authorised medication for insomnia in these disorders.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval